Osteopenia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:38 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Osteopenia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Alendronate on Bone and Blood Sugar Markers in Patients with Diabetes and Osteopenia/Osteoporosis https://clinicaltrials.eu/trial/study-on-the-effects-of-alendronate-on-bone-and-blood-sugar-markers-in-patients-with-diabetes-and-osteopenia-osteoporosis/ Wed, 29 Apr 2026 14:27:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-alendronate-on-bone-and-blood-sugar-markers-in-patients-with-diabetes-and-osteopenia-osteoporosis/ This clinical trial is focused on studying the effects of a treatment on patients with Diabetes Mellitus, which includes both type 1 and type 2 diabetes, and conditions related to bone health such as osteopenia and osteoporosis. The treatment being tested is a medication called Alendronate, which is commonly used to strengthen bones. The study will also involve a comparison with a placebo, which is a substance with no active medication.

The purpose of the study is to investigate how Alendronate affects markers related to bone health and blood sugar control in patients with diabetes. Participants will take the medication in the form of tablets, and the study will monitor changes in their bone and blood sugar markers over time. The study will last for a period of up to 24 months, during which participants will have regular check-ups to assess their health and the effects of the treatment.

Throughout the study, various health indicators will be measured, including HbA1c (a marker of blood sugar levels), bone density, and other substances in the blood that can provide information about bone and metabolic health. The study aims to provide insights into how Alendronate can benefit patients with diabetes who also have concerns about their bone health.

]]> Study on Dasatinib and Quercetin or Nicotinamide Riboside for Patients with Osteoporosis or Osteopenia https://clinicaltrials.eu/trial/study-on-dasatinib-and-quercetin-or-nicotinamide-riboside-for-patients-with-osteoporosis-or-osteopenia/ Wed, 29 Apr 2026 14:25:13 +0000 https://clinicaltrials.eu/trial/study-on-dasatinib-and-quercetin-or-nicotinamide-riboside-for-patients-with-osteoporosis-or-osteopenia/ This clinical trial is focused on studying the effects of a treatment for people with osteoporosis and osteopenia, which are conditions that cause bones to become weak and more likely to break. The treatment being tested includes a medication called dasatinib, which is taken as a film-coated tablet. Dasatinib is known as a protein kinase inhibitor, which means it works by blocking certain proteins that can affect cell growth. In this study, dasatinib is combined with either quercetin or nicotinamide riboside, which are substances that may help improve bone health.

The purpose of this study is to investigate how effective and safe this combination treatment is in reducing bone loss in patients with low bone mass. Participants in the study will be randomly assigned to receive either the treatment or a placebo. The study will last for a period of 20 weeks, during which time participants will take the medication orally. Throughout the study, researchers will monitor changes in markers that indicate bone resorption, which is the process where bone is broken down and its minerals are released into the bloodstream.

By the end of the study, researchers aim to understand how the treatment affects bone health, specifically looking at markers like CTX, which is a circulating marker of bone resorption, and other markers related to bone formation. This information will help determine if the combination of dasatinib with quercetin or nicotinamide riboside can be a beneficial treatment for individuals with osteoporosis or osteopenia.

]]> Study on Dasatinib and Quercetin for Patients with Osteoporosis or Osteopenia https://clinicaltrials.eu/trial/study-on-dasatinib-and-quercetin-for-patients-with-osteoporosis-or-osteopenia/ Wed, 29 Apr 2026 14:24:46 +0000 https://clinicaltrials.eu/trial/study-on-dasatinib-and-quercetin-for-patients-with-osteoporosis-or-osteopenia/ This clinical trial is focused on studying the effects of a treatment on individuals with osteopenia and osteoporosis, which are conditions characterized by low bone mass and increased risk of fractures. The treatment being tested includes a combination of dasatinib, a medication known as a protein kinase inhibitor, and either quercetin or nicotinamide riboside. These substances are being investigated for their potential to improve bone health by reducing bone resorption, which is the process where bone is broken down and its minerals are released into the bloodstream.

The purpose of the study is to evaluate the effectiveness and safety of this treatment in reducing bone resorption in patients with low bone mass. Participants in the study will receive either the treatment or a placebo. The study will last for a period of 21 weeks, during which time various markers of bone health will be monitored. These markers include CTX, a circulating marker of bone resorption, as well as other markers related to bone formation and resorption.

Throughout the study, participants will be monitored to assess changes in these markers, which will help determine the impact of the treatment on bone health. The study aims to provide valuable insights into whether this combination of medications can offer a new approach to managing conditions like osteopenia and osteoporosis, potentially leading to improved therapies for individuals affected by these conditions.

]]>